---
company: Lifeway Foods, Inc.
ticker: LWAY
form: 8-K
filed: 2026-05-14
accession: 0001683168-26-003838
source: https://www.sec.gov/Archives/edgar/data/814586/000168316826003838/
---

# Lifeway Foods (LWAY) earnings release, May 14, 2026

Lifeway Foods, Inc. (LWAY) · Form 8-K, Item 2.02 · Filed 2026-05-14 · [SEC filing](https://www.sec.gov/Archives/edgar/data/814586/000168316826003838/)

Lifeway Foods®

Announces Record-Breaking Results for the First Quarter Ended March 31, 2026

Achieves $63.0 million in net sales, a 37% volume-led net sales increase, driven by the Company’s flagship Lifeway Kefir

Record-breaking results signal robust Kefir &

Farmer Cheese growth, supported by the widening consumer focus on protein-rich, probiotic foods

Significant gross profit margin expansion of 360 basis points and net income growth of 32% reflect the Company’s disciplined operational execution

Morton Grove, IL — May 14, 2026 — Lifeway Foods, Inc. (Nasdaq: LWAY) (“Lifeway” or “the Company”), the leading U.S. supplier of kefir and fermented probiotic foods, today announced financial results for the first quarter ended March 31, 2026.

We kicked off 2026 with a blowout quarter that demonstrates the extraordinary momentum we’ve built across our business,” said Julie Smolyansky, President and Chief Executive Officer of Lifeway Foods.

“We far exceeded our previous record with net sales of $63.0 million, up 37% year-over-year, surpassing sixty million in quarterly net sales for the first time and marking our 26 th consecutive quarter of year-over-year growth. This exceptional top-line performance was accompanied by sizeable gross margin expansion of 360 basis points year-over-year, and equally strong net income growth of 32% that reflects a clean flow-through from our significant sales growth down to the bottom line. We are investing meaningfully behind our core products to support our rapid growth, and we continue to see impressive velocity acceleration. We also leveraged our SG&A by 300 basis points this quarter, demonstrating the increasing return and effectiveness of our investments.”

Ms. Smolyansky continued, “We believe Lifeway is uniquely positioned at the intersection of numerous consumer tailwinds with our on-trend, functional product offerings. The consumer focus on health and wellness continues to increase, gut-health awareness is spreading and demand from GLP-1 users seeking nutrient-dense, probiotic foods is particularly strong. We address each of these trends with our flagship Lifeway Kefir and high-protein Lifeway Farmer Cheese, while continuing to build a pipeline of innovative products, including Muscle Mates™ with creatine and probiotic Kefir Butter™. Together, these offerings bring new excitement to the category and expand our reach across the cultured dairy landscape. We are very excited about our trajectory and confident in our ability to execute throughout 2026 as we further capitalize on the growing consumer demand in our space.”

First Quarter 2026 Highlights

Expanding Lifeway Visibility

Lifeway recently announced strategic partnerships, experiential marketing initiatives, and product innovation designed to elevate the brand’s visibility and engage health-conscious consumers nationwide.

Outlook

The Company reiterated its long-term target of

$45–$50 million in Adjusted EBITDA¹ for FY 2027 and believes it is well positioned to deliver the strongest annual sales in Company history in FY 2026.

“Our momentum continues to build as we drive sustainable, profitable growth across the business,” Smolyansky concluded. “We have laid a foundation for durable, long-term value creation, and believe the investments we are making today in manufacturing capacity, marketing and innovation position us exceptionally well to capitalize on the tremendous opportunities ahead.”

Conference Call and Webcast

A webcast with Lifeway’s President and

Chief Executive Officer discussing these results with additional comments and details is available through the “Investor Relations” section of the Company’s website at https://lifewaykefir.com/webinars-reports/.

About Lifeway Foods, Inc.

Lifeway Foods, Inc., which has been recognized as one of America's Growth Leaders by TIME, as Dairy Foods' Processor of the Year 2025, one of Forbes' Best Small Companies and named to Inc.'s 2025 Best in Business list in the Best Challenger Brands category, is America's leading supplier of the probiotic, fermented beverage known as kefir. In addition to its line of drinkable kefir, the Company also produces a variety of cheeses and a ProBugs® line for kids. Lifeway's tart and tangy fermented dairy products are now sold across the United States, Mexico, United Arab Emirates,

Central America and the Caribbean. Learn how Lifeway is good for more than just you at lifewayfoods.com.

Forward-Looking Statements

This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things, unaudited estimated net sales. These statements use words, and variations of words, such as "anticipate," "plan," "project,"

"estimate," "potential," "forecast," "will," "continue," "future," "increase,"

"believe," "outlook," "expect," and "predict." You are cautioned not to rely on these forward-looking statements. These forward-looking statements are made as of the date of this press release, are based on current expectations of future events and thus are inherently subject to a number of risks and uncertainties, many of which involve factors or circumstances beyond Lifeway's control. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from Lifeway's expectations and projections. These risks, uncertainties, and other factors include: price competition; the decisions of customers or consumers; the actions of competitors; changes in the pricing of commodities; the effects of government regulation; possible delays in the introduction of new products; and customer acceptance of products and services. A further list and description of these risks, uncertainties, and other factors can be found in Lifeway's Annual Report on Form 10-K for the fiscal year ended December... (tr. Copies of these filings are available online at https://www.sec.gov, http://lifewaykefir.com/investor-relations/, or on request from Lifeway. Lifeway expressly disclaims any obligation to update any forward-looking statements (including, without limitation, to reflect changed assumptions, the occurrence of anticipated or unanticipated events or new information), except as required by law.

Non-GAAP Financial Measures

This press release refers to Adjusted EBITDA, which is a financial measure that has not been prepared in accordance with U.S. Generally Accepted Accounting Principles (“GAAP”), and may exclude items that are significant to understanding and assessing financial results. This non-GAAP measure is provided to enhance investors’ overall understanding of the Company’s financial performance. Non-GAAP financial measures should be considered as supplements to GAAP measures reported, should not be considered replacements for, or superior to, GAAP measures reported and may not be comparable to similarly named measures used by other companies. The Company’s calculation of non-GAAP financial measures may differ from methods used by other companies.

We are unable to reconcile our target fiscal year 2027 Adjusted EBITDA to projected net income, the most directly comparable projected GAAP financial measure, because certain information necessary to calculate such measures on a GAAP basis is unavailable or dependent on the timing of future events outside of our control.

Due to this uncertainty, the Company cannot reconcile target fiscal year 2027 Adjusted EBITDA to the nearest GAAP financial measure without unreasonable effort.

Derek Miller

Vice President of Communications, Lifeway

Foods

Email: derekm@lifeway.net

Perceptual Advisors

Dan Tarman

Email: dtarman@perceptualadvisors.com

General inquiries:

Lifeway Foods, Inc.

Phone: 847-967-1010

Email: info@lifeway.net

LIFEWAY FOODS, INC. AND SUBSIDIARIES

Unaudited Consolidated Balance Sheets

March 31, 2026 and December 31, 2025

(In thousands)

LIFEWAY FOODS, INC. AND SUBSIDIARIES

Unaudited Consolidated Statements of Operations

For the three months ended March 31, 2026 and

2025

(In thousands, except per share data)

LIFEWAY FOODS, INC. AND SUBSIDIARIES

Consolidated Statements of Cash Flows

(Unaudited)

(In thousands)

## Financial statements

### Income Statement ((In thousands, except per share data))

| | 2026 | 2025 |
|---|---:|---:|
| Net Sales | 63,012 | 46,091 |
| Cost of goods sold | 44,741 | 34,254 |
| Depreciation expense | 920 | 802 |
| Total cost of goods sold | 45,661 | 35,056 |
| Gross profit | 17,351 | 11,035 |
| Selling expense | 6,188 | 4,698 |
| General and administrative expense | 4,703 | 4,628 |
| Amortization expense | 135 | 135 |
| Total operating expenses | 11,026 | 9,461 |
| Income from operations | 6,325 | 1,574 |
| Other income (expense): | Interest expense | -68 | -14 |
| Other income (expense): | Gain on sales of investments |  | 3,352 |
| Other income (expense): | Other income (expense), net |  | 54 |
| Other income (expense): | Total other (expense) income | -68 | 3,392 |
| Other income (expense): | Income before provision for income taxes | 6,257 | 4,966 |
| Other income (expense): | Provision for income taxes | 1,583 | 1,426 |
| Other income (expense): | Net income | 4,674 | 3,540 |
| Net earnings per common share: | Basic | 0.31 | 0.23 |
| Net earnings per common share: | Diluted | 0.3 | 0.23 |
| Weighted average common shares outstanding: | Basic | 15,257 | 15,134 |
| Weighted average common shares outstanding: | Diluted | 15,559 | 15,333 |

### Balance Sheet (March 31, 2026 — (In thousands) (in thousands))

| | March 31, 2026 – (Unaudited) | December 31, – 2025 |
|---|---:|---:|
| Current assets | Cash and cash equivalents | 5,604 | 5,571 |
| Current assets | Accounts receivable, net of allowance for credit losses and discounts & allowances of $2,530 and $1,730 at March 31, 2026 and December 31, 2025, respectively | 22,985 | 16,643 |
| Current assets | Inventories, net | 11,452 | 11,890 |
| Current assets | Prepaid expenses and other current assets | 2,588 | 2,627 |
| Current assets | Refundable income taxes | 41 | 325 |
| Current assets | Total current assets | 42,670 | 37,056 |
| Current assets | Property, plant and equipment, net | 57,844 | 48,282 |
| Current assets | Operating lease right-of-use asset | 553 | 465 |
| Current assets | Goodwill | 11,704 | 11,704 |
| Current assets | Intangible assets, net | 5,683 | 5,818 |
| Current assets | Other assets | 2,051 | 2,285 |
| Current assets | Total assets | 120,505 | 105,610 |
| Current liabilities | Accounts payable | 13,845 | 11,008 |
| Current liabilities | Accrued expenses | 4,589 | 5,413 |
| Current liabilities | Accrued income taxes | 1,518 | 218 |
| Current liabilities | Total current liabilities | 19,952 | 16,639 |
| Current liabilities | Line of credit | 6,939 |  |
| Current liabilities | Operating lease liabilities | 426 | 360 |
| Current liabilities | Deferred income taxes, net | 2,792 | 2,792 |
| Current liabilities | Other long-term liabilities | 74 |  |
| Current liabilities | Total liabilities | 30,183 | 19,791 |
| Stockholders’ equity | Common stock, no par value; 40,000 shares authorized; 17,274 shares issued; 15,282 and 15,232 outstanding at March 31, 2026 and December 31, 2025, respectively | 6,509 | 6,509 |
| Stockholders’ equity | Treasury stock, at cost | -12,889 | -13,214 |
| Stockholders’ equity | Paid-in capital | 3,347 | 3,843 |
| Stockholders’ equity | Retained earnings | 93,355 | 88,681 |
| Stockholders’ equity | Total stockholders’ equity | 90,322 | 85,819 |
| Stockholders’ equity | Total liabilities and stockholders’ equity | 120,505 | 105,610 |

### Cash Flow (Three months ended March 31, — (In thousands) (in thousands))

| | Three months ended March 31, – 2026 | Three months ended March 31, – 2025 |
|---|---:|---:|
| Cash flows from operating activities: | Net income | 4,674 | 3,540 |
| Adjustments to reconcile net income to operating cash flow: | Depreciation and amortization | 1,055 | 937 |
| Adjustments to reconcile net income to operating cash flow: | Stock-based compensation | 548 | 326 |
| Adjustments to reconcile net income to operating cash flow: | Non-cash interest expense | 5 | 3 |
| Adjustments to reconcile net income to operating cash flow: | Bad debt expense | 87 |  |
| Adjustments to reconcile net income to operating cash flow: | Gain on sale of investments |  | -3,352 |
| Adjustments to reconcile net income to operating cash flow: | Fair value loss on investment |  | 20 |
| (Increase) decrease in operating assets: | Accounts receivable | -6,429 | -1,259 |
| (Increase) decrease in operating assets: | Inventories | 438 | -563 |
| (Increase) decrease in operating assets: | Prepaid expenses and other current assets | 228 | 136 |
| (Increase) decrease in operating assets: | Refundable income taxes | 283 | 631 |
| Increase (decrease) in operating liabilities: | Accounts payable | 3,397 | 1,401 |
| Increase (decrease) in operating liabilities: | Accrued expenses | -1,282 | -2,765 |
| Increase (decrease) in operating liabilities: | Accrued income taxes | 1,300 | 795 |
| Increase (decrease) in operating liabilities: | Other long-term liabilities | 74 |  |
| Increase (decrease) in operating liabilities: | Net cash provided by (used in) operating activities | 4,378 | -150 |
| Cash flows from investing activities: | Purchases of property and equipment | -11,041 | -2,219 |
| Cash flows from investing activities: | Proceeds from sale of investments |  | 5,152 |
| Cash flows from investing activities: | Net cash (used in) provided by investing activities | -11,041 | 2,933 |
| Cash flows from financing activities: | Borrowings under line of credit | 8,000 |  |
| Cash flows from financing activities: | Repayments under line of credit | -1,000 |  |
| Cash flows from financing activities: | Payment of deferred financing costs | -21 | -65 |
| Cash flows from financing activities: | Equity award settled in cash | -283 |  |
| Cash flows from financing activities: | Net cash provided by (used in) financing activities | 6,696 | -65 |
| Cash flows from financing activities: | Net increase in cash and cash equivalents | 33 | 2,718 |
| Cash flows from financing activities: | Cash and cash equivalents at the beginning of the period | 5,571 | 16,728 |
| Cash flows from financing activities: | Cash and cash equivalents at the end of the period | 5,604 | 19,446 |
| Supplemental cash flow information: | Cash paid for income taxes, net of (refunds) | $– | $– |
| Supplemental cash flow information: | Cash paid for interest | 45 | 11 |
